Senate Finance Committee Staff Report On GlaxoSmithKline and The Diabetes Drug Avandia – Links to Original Documents

Today the New York Times published some of the findings of a report conducted by the Senate Finance Committee Staff on the Diabetes Drug Avandia that was scheduled to be released on Monday.

The report is critical of GlaxoSmithKline’s internal procedures.  It is also critical of the FDA’s procedures on adjudicating drug safety issues.

We will be providing a full analysis in the coming days.

Subsequently the report and supporting documents were released today by the Senate Finance Committee. 

Bellow are the links to the relevant documents:

Grassley, Baucus release committee report on Avandia 2/20/10

Full Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia 2/20/10

Senators’ letter to the FDA with attachments 2/20/10